Loading
Theraclion Stock: price and insider trades · France
No insider purchase over the last 90 days. The latest was filed 17 Apr 2026.
Theraclion: what insiders have been doing
Theraclion belongs to the Healthcare & Pharma sector. Filings by its managers are published through AMF. 3 insiders have disclosed 8 filings since 18 October 2025.
Both sides are active: 1 purchase and 4 sales worth €44k, from 1 insider and 1 insider respectively. No amount is published for 1 filing, which the totals therefore leave out. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. The buyers include 1 chief executive. One trade stands out by size: a sale of €20k from Cedric Bellanger, disclosed on 11 June 2026, or 0.036% of market capitalisation.
Across the 316 companies tracked on its exchange, the median is 6 filings; at 8 filings, this issuer sits above that mark. The full history, which starts in 2021, counts 5 purchases against 14 sales.
The last insider purchase was made public on 17 April 2026, 183 days ago. Between a trade and the moment it shows up on AMF, the median delay is 5 days. Under the Market Abuse Regulation, managers have three business days to notify their trades. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify.
In the same sector, recent insider purchases at Cooper Companies, Inc. and Cytosorbents Corp also feature in our signals. These figures are compiled from regulatory filings published by AMF. They describe what insiders did and are not a recommendation.
Insider Decl.
39
Thresholds
n/a
Buy Volume
€59,317
5 ops. · all time
Sell Volume
€134,347
14 ops. · all time
Who traded when
BuySaleCedric Bellanger4 sales
Martin Deterre1 buy
Financial data
as of FY 2025FY ended December 2025 · cache
€0.65
Analyst consensus
Income statement
Revenue€1.2M
Gross profit-€2.9M-241% margin
EBITDA-€5.1M-429% margin
Net income-€5.7M-479.8% margin
Valuation
Beta0.45
Balance sheet & cash
Market cap€48.0M
Total debt€4.9M
Free Cash Flow-€7.2M
Profitability & ownership
ROA-40.4%
% insiders67.8%
% institutions0.0%
Last declaration on 27 August 2026
Declarations39 total
266,139 shares@ €0.20100.0% of flowActionEuronext ParisISIN FR00101204022026DD1134988
25,000 shares@ €0.800.036% mcap25.2% of flowActionEuronext Growth ParisISIN FR00101204022026DD1120140
25,207 shares@ €0.700.042% mcap22.2% of flowActionEuronext Growth ParisISIN FR00101204022026DD1117574
6,321 shares@ €0.480.0072% mcap100.0% of flowActionteneur de registre upteviaISIN FR00101204022026DD1114431
21,000 shares@ €0.480.024% mcap12.7% of flowActionEuronext Growth ParisISIN FR00140180M62026DD1113499
288,352 shares0ActionCréation d'actions au nominatif liées à un plan d'actions gratuitesISIN FR00101204022026DD1108395
Canonical exit: 12 Jul 2026 (T+90)
7,339 shares@ €0.700.011% mcap6.5% of flowActionEuronext Growth ParisISIN FR00101204022026DD1101548
1,493 shares@ €0.960.0031% mcap1.8% of flowActionEuronext Growth ParisISIN FR00101204022026DD1101549
138,961 shares0ActionCréation des actions au nominatifISIN FR00101204022025DD1051051
335,484 shares0ActionEuronext Growth ParisISIN FR00101204022025DD1050307
122.747 shares@ €0.400.1% of flowActionHors plateforme de négociationISIN FR00101204022024DD970484
63,652 shares0ActionHors plateforme de négociationISIN FR00101204022024DD949094
50,380 shares0ActionHors plateforme de négociationISIN FR00101204022024DD948788
Canonical exit: 13 Feb 2024 (T+90)
65,417 shares@ €0.50278.2% of flowActionHors plateforme de négociationISIN FR00101204022024DD948364
Canonical exit: 25 Apr 2024 (T+90)
96,342 shares@ €1.12124.2% of flowActionHors plateforme de négociationISIN FR00101204022024DD944728
108,800 shares@ €1.2530.5% of flowTitre de créanceEuronext Growth ParisISIN FR00101204022022DD840683
22,747 shares@ €1.09931.5% of flowActionEuronext Growth ParisISIN FR00101204022022DD824631
Canonical exit: 30 May 2022 (T+90)
40,764 shares@ €1.099100.0% of flowActionEuronext Growth ParisISIN FR00101204022022DD824645
11,989 shares@ €1.099100.0% of flowActionEuronext Growth ParisISIN FR00101204022022DD824646
181,983 shares@ €1.09944.9% of flowActionEuronext Growth ParisISIN FR00101204022022DD824339
1,000 shares@ €1.47920.3% of flowActionEuronext Growth ParisISIN FR00101204022022DD824346
Canonical exit: 16 May 2022 (T+90)
181,983 shares@ €1.099100.0% of flowActionEuronext Growth ParisISIN FR00101204022022DD824030
5,459 shares@ €1.0993.5% of flowActionEuronext Growth ParisISIN FR00101204022022DD823902
10,000 shares@ €1.458.4% of flowActionEuronext Access ParisISIN FR00101204022021DD798413
9,676 shares@ €1.428.0% of flowActionEuronext Growth ParisISIN FR00101204022021DD798416
25 of 39 declarations
About Theraclion
Theraclion is a French medtech company focused on non-invasive medical treatment using focused ultrasound and robotics. Listed on Euronext Growth Paris under ISIN FR0010120402, the company develops extracorporeal surgery platforms designed to replace, in selected indications, more invasive procedures performed in an operating room. Its market positioning is built around a clear value proposition: reduce invasiveness, lower healthcare-system costs, and improve the patient journey through treatments that require no incision, leave no scar, and allow rapid recovery.
Theraclion’s history dates back to 2004, when the research phase began. The company then reached several industrial and clinical milestones, including delivery of ECHOPULSE in 2014, the launch of SONOVEIN in 2019, and the introduction of SONOVEIN HD in 2022. The company is headquartered in Malakoff, near Paris, where its management, research, operations, and regulatory teams are based. This evolution shows a gradual transition from laboratory innovation to a commercial medical-device offering aimed at hospitals, specialty centers, and certain office-based practices.
Read moreShow less
Theraclion’s product portfolio is organized around two main platforms. SONOVEIN is its robotic echotherapy system for the treatment of varicose veins, which the company describes as a 100% non-invasive solution. ECHOPULSE targets thyroid nodules and breast fibroadenomas. Today, Theraclion’s industrial and commercial strategy is primarily centered on SONOVEIN, which is the main driver of growth and international expansion. According to the company, the platform is now present in more than 10 countries, and more than 15 countries in some recent communications, underscoring the ongoing geographic rollout beyond France.
From a competitive standpoint, Theraclion operates in a highly specialized niche at the intersection of healthcare, medical imaging, robotics, and therapeutic ultrasound. Its differentiation lies in SONOVEIN’s non-invasive profile, real-time imaging integration, and workflow designed to be handled by a single operator without the need for an operating room or anesthesia. In 2026, the company also announced a €6 million capital increase, highlighting the financing needs typically associated with development-stage medtech companies and commercial scale-up. For investors, Theraclion remains a speculative growth stock, exposed to regulatory, clinical, and commercialization risks, but supported by a distinctive technology platform in non-invasive treatment of venous disease.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
